Literature DB >> 28701569

Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.

Xia Liu1, Julia Y S Tsang2, Thazin Hlaing3, Jintao Hu4, Yun-Bi Ni2, Siu Ki Chan5, Sai Yin Cheung6, Gary M Tse7.   

Abstract

BACKGROUND: The presence of tumor infiltrating lymphocytes (TIL) is associated with favorable prognosis. Recent evidence suggested that not only their density, but also the spatial organization as tertiary lymphoid structures (TLS), play a key role in determining patient survival.
MATERIALS AND METHODS: In a cohort of 248 breast cancers, the clinicopathologic association and prognostic role of TLS was examined.
RESULTS: Tertiary lymphoid structures were associated with higher tumor grade, apocrine phenotype, necrosis, extensive in situ component, lymphovascular invasion (LVI), and high TIL. For biomarkers, TLS were associated with hormone receptors negativity, HER2 positivity, and c-kit expression. Tertiary lymphoid structures were significantly related to better disease-free survival (DFS) in HER2 positive (HER2+) breast cancers (log-rank = 4.054), which was not dependent on high TIL status. The combined TLS and TIL status was an independent favorable factor associated with DFS in those cases. Interestingly, tumor cell infiltration into the TLS was found in 41.9% of TLS positive cases. It was associated with LVI in HER2 negative (HER2-) TLS positive (particularly estrogen receptor positive [ER+] HER2-) cases. In the ER+ HER2- cases, tumor cell infiltration into TLS was also associated with increased pathologic nodal stage (pN) stage and nodal involvement.
CONCLUSION: Tertiary lymphoid structures showed a similar relationship with clinicopathologic features and biomarkers as TIL. The presence of TLS, irrespective of TIL level, could be an important favorable prognostic indicator in HER2+ breast cancer patients. Given the significance of TLS in promoting effective antitumor immunity, further understanding of its organization and induction may provide new opportunities to improve the current immunotherapy strategies. IMPLICATIONS FOR PRACTICE: Despite recent interest on the clinical value of tumor infiltrating lymphocyte (TIL), little was known on the clinical significance on their spatial organization as tertiary lymphoid structures (TLS). Although TLS showed similar relationships with clinicopathologic features and biomarkers as TIL, the prognostic value of TLS, particularly in HER2 positive cancers, was independent of TIL. Moreover, tumor infiltration could be present in TLS which appears to be related to tumor invasion in HER2 negative cancers. Overall, the results demonstrated the additional value for TLS in HER2 cancer subtypes. Further investigations and its standardized evaluation will enhance its use as standard practice. © AlphaMed Press 2017.

Entities:  

Keywords:  Breast cancer; Human epidermal growth receptor 2 positive cancers; Tertiary lymphoid organ; Tumor infiltrating lymphocyte

Mesh:

Substances:

Year:  2017        PMID: 28701569      PMCID: PMC5679825          DOI: 10.1634/theoncologist.2017-0029

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  29 in total

1.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

2.  Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.

Authors:  Hee Jin Lee; Joo Young Kim; In Ah Park; In Hye Song; Jong Han Yu; Jin-Hee Ahn; Gyungyub Gong
Journal:  Am J Clin Pathol       Date:  2015-08       Impact factor: 2.493

3.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

4.  Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.

Authors:  Jérémy Goc; Claire Germain; Thi Kim Duy Vo-Bourgais; Audrey Lupo; Christophe Klein; Samantha Knockaert; Luc de Chaisemartin; Hanane Ouakrim; Etienne Becht; Marco Alifano; Pierre Validire; Romain Remark; Scott A Hammond; Isabelle Cremer; Diane Damotte; Wolf-Herman Fridman; Catherine Sautès-Fridman; Marie-Caroline Dieu-Nosjean
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

5.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

Review 6.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Authors:  Peter Savas; Roberto Salgado; Carsten Denkert; Christos Sotiriou; Phillip K Darcy; Mark J Smyth; Sherene Loi
Journal:  Nat Rev Clin Oncol       Date:  2015-12-15       Impact factor: 66.675

7.  Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients.

Authors:  Stine L Figenschau; Silje Fismen; Kristin A Fenton; Christopher Fenton; Elin S Mortensen
Journal:  BMC Cancer       Date:  2015-03-06       Impact factor: 4.430

Review 8.  Tertiary lymphoid organs in infection and autoimmunity.

Authors:  Katrijn Neyt; Frédéric Perros; Corine H GeurtsvanKessel; Hamida Hammad; Bart N Lambrecht
Journal:  Trends Immunol       Date:  2012-05-21       Impact factor: 16.687

9.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

Review 10.  Tertiary Lymphoid Organs in Cancer Tissues.

Authors:  Nobuyoshi Hiraoka; Yoshinori Ino; Rie Yamazaki-Itoh
Journal:  Front Immunol       Date:  2016-06-22       Impact factor: 7.561

View more
  27 in total

Review 1.  Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.

Authors:  Anthony B Rodriguez; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2020-11       Impact factor: 11.151

Review 2.  Immunological Landscape of HER-2 Positive Breast Cancer.

Authors:  Santiago Moragon; Cristina Hernando; Maria Teresa Martinez-Martinez; Marta Tapia; Belen Ortega-Morillo; Ana Lluch; Begoña Bermejo; Juan Miguel Cejalvo
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 3.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

Review 4.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

5.  Oral cancer-associated tertiary lymphoid structures: gene expression profile and prognostic value.

Authors:  K Li; Q Guo; X Zhang; X Dong; W Liu; A Zhang; Y Li; J Yan; G Jia; Z Zheng; W Tang; L Pan; M An; B Zhang; S Liu; B Fu
Journal:  Clin Exp Immunol       Date:  2019-11-08       Impact factor: 4.330

Review 6.  Tertiary lymphoid structures in the era of cancer immunotherapy.

Authors:  Catherine Sautès-Fridman; Florent Petitprez; Julien Calderaro; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

7.  Relationship between Tertiary Lymphoid Structure and the Prognosis and Clinicopathologic Characteristics in Solid Tumors.

Authors:  Zhan Zhao; Hui Ding; Zheng-Bin Lin; Sheng-Hui Qiu; Yi-Ran Zhang; Yan-Guan Guo; Xiao-Dong Chu; Loi I Sam; Jing-Hua Pan; Yun-Long Pan
Journal:  Int J Med Sci       Date:  2021-04-07       Impact factor: 3.738

Review 8.  Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy.

Authors:  Shota Aoyama; Ryosuke Nakagawa; James J Mulé; Adam W Mailloux
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

Review 9.  The neglected brothers come of age: B cells and cancer.

Authors:  Shabnam Shalapour; Michael Karin
Journal:  Semin Immunol       Date:  2021-06-29       Impact factor: 10.671

Review 10.  Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.

Authors:  Charlotte Domblides; Juliette Rochefort; Clémence Riffard; Marylou Panouillot; Géraldine Lescaille; Jean-Luc Teillaud; Véronique Mateo; Marie-Caroline Dieu-Nosjean
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.